Education
About Us
Working with TipRanks
Follow Us
Lifecore Biomedical (LFCR)
NASDAQ:LFCR
LFCR Stock Chart & Stats
$7.72
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.72
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$4.76 - $8.85
Previous CloseN/A
Volume140.23K
Average Volume (3M)204.26K
Market Cap
$254.02M
Enterprise Value$418.81M
Total Cash (Recent Filing)$18.86M
Total Debt (Recent Filing)$137.53M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Jan 01, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding37,466,350
10 Day Avg. Volume178,832
30 Day Avg. Volume204,257
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)4.93
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.65
Enterprise Value/Revenue3.10
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda-59.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
New ContractsLifecore signed two new programs during the quarter and two additional programs after the quarter ended, including a potentially lucrative commercial site transfer contract.
Revenue GrowthLifecore Biomedical's top-line growth in CDMO was driven by higher sales volumes and an increase related to pricing and other revenue.
Strategic DevelopmentsLifecore Biomedical's facility is currently underutilized at approximately 20%, positioning it to potentially win significant business in the future.
Bears Say
Earnings PerformanceReported EPS came in at -$0.29 versus the estimated -$0.19.
Financial LeverageRecommendation to maintain LFCR shares at MARKET PERFORM is due to Lifecore's significant leverage and valuation concerns.
Revenue TimingThe anticipated ramp in revenue for Lifecore Biomedical may not occur until fiscal year 2027.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical’s price range in the past 12 months?
Lifecore Biomedical lowest stock price was $4.76 and its highest was $8.85 in the past 12 months.
What is Lifecore Biomedical’s market cap?
Lifecore Biomedical’s market cap is $254.02M.
When is Lifecore Biomedical’s upcoming earnings report date?
Lifecore Biomedical’s upcoming earnings report date is Jan 01, 2026 which is in 28 days.
How were Lifecore Biomedical’s earnings last quarter?
Lifecore Biomedical released its earnings results on Nov 06, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.313 by $0.023.
Is Lifecore Biomedical overvalued?
According to Wall Street analysts Lifecore Biomedical’s price is currently Overvalued.
Does Lifecore Biomedical pay dividends?
Lifecore Biomedical does not currently pay dividends.
What is Lifecore Biomedical’s EPS estimate?
Lifecore Biomedical’s EPS estimate is -0.17.
How many shares outstanding does Lifecore Biomedical have?
Lifecore Biomedical has 37,466,350 shares outstanding.
What happened to Lifecore Biomedical’s price movement after its last earnings report?
Lifecore Biomedical reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.313. Following the earnings report the stock price went up 3.474%.
Which hedge fund is a major shareholder of Lifecore Biomedical?
Currently, no hedge funds are holding shares in LFCR
Lifecore Biomedical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Increased
By 30.0K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
28.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.55%
Trailing 12-Months
Company Description
Lifecore Biomedical
Lifecore Biomedical (LFCR) is a leading biotechnology company specializing in the development and manufacturing of high-quality hyaluronic acid-based products. The company operates primarily in the healthcare sector, focusing on regenerative medicine, medical devices, and pharmaceutical applications. Lifecore's core offerings include a range of injectable dermal fillers, surgical lubricants, and viscoelastic products that serve various medical needs, particularly in orthopedics and aesthetics.
LFCR Company Deck
LFCR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant strategic advancements in customer partnerships, pipeline progress, and operational efficiencies, suggesting a focus on long-term growth. However, the quarter experienced a decline in revenue and a net loss, influenced by specific non-recurring adjustments and increased SG&A expenses. Overall, the sentiment reflects cautious optimism, balancing growth initiatives with current financial challenges.View all LFCR earnings summariesLFCR Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.32% Insiders
6.68% Mutual Funds
45.20% Other Institutional Investors
24.44% Public Companies and
Individual Investors